Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.32 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | ATM | Q13315 | 1/20 | 0.31 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21945145 | 0.92 | ALDH1A1 (0.41) | KDM4ESMN1; SMN2ALDH1A1GAAMAPT | |
| SCHEMBL21944845 | 0.90 | KDM4E (0.39) | KDM4ESMN1; SMN2ALDH1A1MAPT | |
| SCHEMBL21944838 | 0.84 | DBH (0.34) | KDM4EALDH1A1GAAMAPTATM | |
| SCHEMBL21945142 | 0.84 | CYP11B1 (0.34) | MAPT | |
| SCHEMBL21945111 | 0.84 | ROCK2 (0.35) | — | |
| SCHEMBL21944841 | 0.84 | C5AR1 (0.32) | — | |
| SCHEMBL21945238 | 0.83 | CYP11B1 (0.34) | KDM4EHTTALDH1A1GAAMAPT | |
| SCHEMBL21945146 | 0.83 | HDAC3 (0.37) | ALDH1A1GAAHSP90AA1HSP90AB1MAPT | |
| SCHEMBL21945141 | 0.81 | ALDH1A1 (0.38) | ALDH1A1 | |
| SCHEMBL21945240 | 0.81 | ATM (0.41) | KDM4ESMN1; SMN2HTTALDH1A1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4219477-A1 | CYANOTRIAZOLE COMPOUNDS | Otsuka Pharmaceutical Co., Ltd. (JP) | 2023-08-02 | — | — | EP | disclosed |
| US-10626095-B2 | Cyanotriazole compounds | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2020-04-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10626095-B2 | Cyanotriazole compounds | CS, PC, ACAT1 | KDM4E 2681/4885SMN1; SMN2 3834/4885HTT 1138/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.